Also trades as: 000028.SZ (SHZ) · $vol 9M
200028.SZ SHZ
China National Accord Medicines Corporation Ltd.
1W: +0.0%
1M: +0.6%
3M: +1.9%
YTD: -14.6%
1Y: -10.8%
3Y: -8.3%
5Y: -16.2%
HK$11.98 ($1.53)
+0.04 (+0.34%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$3.3B
+11.4% ▲
5Y CAGR: +10.3%
Capital Expenditures
$283M
+12.3% ▲
5Y CAGR: +2.9%
Free Cash Flow
$3.0B
+14.3% ▲
5Y CAGR: +11.2%
Dividends Paid
$604M
-8.0% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
$1.3B
+227.7% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $1.7B | $1.5B | $1.8B | $2.0B | $237M |
| Depreciation & Amort. | $1.1B | $1.3B | $1.3B | $1.4B | $1.5B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$1.3B | -$1.3B | -$1.0B | -$520M | $2M |
| Other Non-Cash Items | $7M | $178M | $496M | $73M | $1.5B |
| Operating Cash Flow | $1.5B | $1.7B | $2.6B | $2.9B | $3.3B |
| — Investing Activities — | |||||
| Capital Expenditures | -$294M | -$370M | -$322M | -$322M | -$283M |
| Acquisitions (Net) | -$2.6B | -$110M | -$126M | $0 | -$71M |
| Investment Purchases | -$50M | -$147M | -$75M | -$9M | -$14M |
| Investment Sales | $179M | $172M | $165M | $160M | $208M |
| Other Investing | $28M | -$235K | $16M | $35M | $9M |
| Investing Cash Flow | -$2.8B | -$456M | -$343M | -$135M | -$151M |
| — Financing Activities — | |||||
| Net Debt Issuance | $374M | -$1.2B | -$17M | $84M | -$15M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$550M | -$611M | -$574M | -$559M | -$604M |
| Other Financing | -$1.6B | -$94M | -$916M | -$1.9B | -$1.2B |
| Financing Cash Flow | -$1.7B | -$1.9B | -$1.5B | -$2.4B | -$1.8B |
| Net Change in Cash | -$3.0B | -$672M | $709M | $393M | $1.3B |
| Cash End of Period | $5.4B | $4.7B | $5.4B | $5.8B | $7.1B |
| Free Cash Flow | $1.2B | $1.3B | $2.2B | $2.6B | $3.0B |